Prostatic Hyperplasia - 25 Studies Found Active, not recruiting : Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia : Benign Prostatic Hyperplasia : 2014-07-29 : Drug: Embozene Microspheres Intraarterial application Completed : Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia : Benign Prostatic Hyperplasia : 2008-08-07 : Drug: Doxazosin Treatment with Completed : Saw Palmetto Extract in Benign Prostatic Hyperplasia : Benign Prostatic Hyperplasia : 2002-05-16 : Drug: Saw Palmetto Not yet recruiting : Prostatic Hyperplasia Treatment and Cancer Prevention : Prostatic Hyperplasia : 2016-12-12 : Other: Placebo observation of Terminated : Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia : Benign Prostatic Hyperplasia : 2005-10-10 : Drug: Lonidamine Completed : Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia : Benign Prostatic Hyperplasia : 2009-04-27 : Drug: PRX302 PRX302 will be ad Completed : Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia : Prostatic Hyperplasia : 2011-04-07 : Drug: 5ARI + AB 5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin Completed : Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia : Prostatic Hyperplasia : 2006-11-13 : Drug: alfuzosin Completed : Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) : Benign Prostatic Hyperplasia : 2011-02-21 : Drug: combination therapy alph Completed : Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia : Benign Prostatic Hyperplasia : 2006-10-09 : Drug: Tadalafil 20 mg tadalafi Next >>>
